Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alkermes, Inc.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Agree to use an approved method of contraception for the duration of the study
Have the potential to safely benefit from the administration of ALKS 5461
Have a diagnosis of major depressive disorder (MDD)
Additional criteria may apply
You may not be if
Have a positive test for drugs of abuse
Currently pregnant or breastfeeding
Have a current primary Axis-I disorder other than MDD
Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days
Have received electroconvulsive therapy treatment within the last 2 years, or received more than 1 course of electroconvulsive treatment during their lifetime
Have attempted suicide within the past 2 years
Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)
Have had a significant blood loss or blood donation within the past 60 days
Additional criteria may apply
Clareo Health | A Long-Term Safety Study of ALKS 5461
